The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Ok appreciate the enthusiasm but what does the confirmation statement have to do with any ducks in rows. It is simply a required annual filing and quite often one of the most boring company documents. Following this board and waiting for company updates is made insane by this bs.
When you look again at all the areas this company is innovating in, these guys should be shouting from the rooftops. Hopefully the presentation upcoming is bringing test results, looking forward to seeing what has been achieved. I must admit the quiet demeanor of Marku was something I valued but sometimes I want him to just kick some ass (WHO) and tell the world.
Appreciate that there is considered reflection here (unlike some of the mental threads on eua!) and a company that is concerned with good science and truth. But anyone got any ideas - SNG rise must be interferon but diddly move here, let's have some buzz farn! Doing great work but all quiet
Gkb interesting point as at what stage does the company have to take some responsibility in ensuring their treatments are used properly or atleast used(!) and then getting out/withdrawing if not. I have no idea how plausable withdrawing is in reality, but reputationally clearly the damage is huge and ultimately means poor treatment for patients...
I wouldn't say that so definitively, looking back at the RNS from 2feb this year what has just occurred in the who study beggars belief...
Company notes with interest a recent recommendation by the World Health Organization (WHO) that steroids should not be used on coronavirus infected patients1. One of the main first lines of defence against viral infection is endogenous IFN-beta production2. Blocking endogenous IFN-beta production using steroids may be deleterious to treatment outcomes in these patients. Therefore, exogenous IFN-beta (like Traumakine) can strengthen further this endogenous IFN-beta action and provide maximal protection against viral infections but it has to be administered without concomitant corticosteroids, which have the capacity to disturb or block IFN-beta action.
A recent descriptive study published in The Lancet3 on the 2019 novel coronavirus (2019-nCoV) outbreak in Wuhan, China reports that 17% of the 99 patients with 2019-nCoV pneumonia developed Acute Respiratory Distress Syndrome ("ARDS") and 11% worsened in a short period of time and died of multiple organ failure. 19% of patients in the study received corticosteroids, a treatment option no longer recommended by the WHO.
Dr. Markku Jalkanen, Faron's CEO, said: "With no currently approved pharmacological treatments available, ARDS remains a significant problem for patients and healthcare systems. We are pleased to note that the WHO has recognised the risk of using corticosteroids on patients with coronavirus, which aligns with our findings from post-hoc analysis of the INTEREST study.
"One of the main first lines of defence against viral infection is endogenous interferon-beta production. Faron believes Traumakine treatment, in the absence of concomitant corticosteroid use, can further strengthen this endogenous IFN-beta action and provide increased protection against serious lung complications arising from viral infections. Faron remains committed to developing Traumakine for the potentially fatal condition ARDS."